TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC-Reference-Cited by-同舟云学术

TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC

Published:2020-01-21 Issue:3 Volume:11 Page:250-264
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Roeper Julia¹²³,Falk Markus⁴³,Chalaris-Rißmann Athena⁴³,Lueers Anne C.¹²,Ramdani Hayat¹²³,Wedeken Katrin⁵,Stropiep Ursula²³,Diehl Linda⁶,Tiemann Markus⁴³,Heukamp Lukas C.⁴³,Otto-Sobotka Fabian⁷,Griesinger Frank¹²³

Affiliation:

1. Department of Internal Medicine-Oncology, Carl v. Ossietzky University of Oldenburg, Oldenburg, Germany

2. Department of Hematology and Oncology, Pius-Hospital, Oldenburg, Germany

3. Lung Cancer Network NOWEL.org, Oldenburg, Germany

4. Institute of Hematopathology Hamburg, Hamburg, Germany

5. Department of Tumor Documentation, Cancer Center Oldenburg, Pius Hospital Oldenburg, Oldenburg, Germany

6. Institute of Experimental Immunology and Hepatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

7. Division of Epidemiology and Biometry, Carl v. Ossietzky University of Oldenburg, Oldenburg, Germany

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of TP53 mutation on efficacy and survival in advanced EGFR‐mutant non‐small cell lung cancer patients treated with third‐generation EGFR tyrosine kinase inhibitors;MedComm;2024-06

2. Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO);ESMO Open;2024-06

3. Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report;Frontiers in Oncology;2024-05-06

4. Optimal First-Line Treatment for EGFR-Mutated NSCLC: A Comparative Analysis of Osimertinib and Second-Generation EGFR-TKIs;2024-01-22

5. Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies;British Journal of Cancer;2023-11-08